Jiangsu Langyan Life Technology Holdings Co., Ltd.

Primary objective: To evaluate the pharmacokinetic (PK) effects of a high-fat diet on a single oral dose of NHKC-1 tablets in healthy Chinese adult subjects. Secondary objective: To evaluate the PK characteristics of a single oral dose of NHKC-1 tablets taken in healthy Chinese adult subjects, whether fasting or after a meal. To evaluate the safety and tolerability of a single oral dose of NHKC-1 tablets in healthy Chinese adult subjects.

The study will evaluate the superiority of the investigational drug compared to the placebo, as well as the non-inferiority of the investigational drug compared to the positive control drug. Simultaneously, the safety of the investigational drug, the positive control drug, and the placebo in relieving knee osteoarthritis pain will be evaluated.

Primary Study Objective: To evaluate the pharmacokinetic characteristics, relative bioavailability, and interactions of a single fasting oral dose of NHKC-1, amlodipine besylate tablets (Norvasc), valsartan tablets (DIOVAN), and valsartan capsules (Diovan) in healthy adult Chinese subjects. Secondary Study Objective: To evaluate the safety of fasting oral administration of NHKC-1, amlodipine besylate tablets (Norvasc), valsartan tablets (DIOVAN), and valsartan capsules (Diovan) in healthy adult Chinese subjects.